Search research articles
Contact Us
Filters
Showing results (491-500 of 512) with videos related to
Page
of 52
Sort By:
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
The Lancet. Respiratory Medicine
|
March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Anne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Nature Medicine
|
February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Molecular Oncology
|
September 13, 2021
The Porto European Cancer Research Summit 2021
Ulrik Ringborg, Anton Berns, Julio E Celis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi, Julie Milia, Thomas Filleron, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.
Cell
|
June 21, 2024
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Filippo G Dall'Olio, Wael Zrafi, Veronique Roelants, et al.
Page
of 52
Search research articles
Search
Showing results (491-500 of 512) with videos related to
Sort By:
Page
of 52
The Lancet. Oncology
|
December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
The Lancet. Respiratory Medicine
|
March 27, 2026
Consensus definition of stage III non-small-cell lung cancer technical resectability to standardise inclusion criteria for clinical trials: a multisocietal EORTC-Lung Cancer Group collaboration
Anne-Marie C Dingemans, Isabelle Opitz, Alessandro Brunelli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion
Mihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Nature Medicine
|
February 13, 2024
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 4, 2025
Amivantamab Plus Lazertinib in Patients With EGFR-Mutant NSCLC After Progression on Osimertinib and Platinum-Based Chemotherapy: Results From CHRYSALIS-2 Cohort A
Benjamin Besse, Koichi Goto, Yongsheng Wang, et al.
Molecular Oncology
|
September 13, 2021
The Porto European Cancer Research Summit 2021
Ulrik Ringborg, Anton Berns, Julio E Celis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 28, 2017
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi, Julie Milia, Thomas Filleron, et al.
The New England Journal of Medicine
|
August 27, 2020
Efficacy of Selpercatinib in <i>RET</i> Fusion-Positive Non-Small-Cell Lung Cancer
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, et al.
Cell
|
June 21, 2024
Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome
Lisa Derosa, Valerio Iebba, Carolina Alves Costa Silva, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Metabolic Tumor Volume Assessed by 18F FDG-PET CT Scan as a Predictive Biomarker for Immune Checkpoint Blockers in Advanced NSCLC and Its Biological Correlates
Filippo G Dall'Olio, Wael Zrafi, Veronique Roelants, et al.
Page
of 52